Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.38 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122308 | 0.85 | KDM5A (0.55) | KDM5AMAPTTP53 | |
| SCHEMBL2123093 | 0.83 | CFTR (0.47) | KDM5AMAPTTP53RXFP1MEN1 | |
| SCHEMBL2866440 | 0.83 | KDM5A (0.54) | KDM5AMAPTTP53 | |
| SCHEMBL2122450 | 0.82 | KDM5A (0.51) | KDM5AMAPTTP53POLBGAA | |
| SCHEMBL2123358 | 0.81 | KDM5A (0.50) | KDM5AMAPTTP53KMT2AGAA | |
| SCHEMBL2125958 | 0.81 | KDM5A (0.48) | KDM5AMAPTTP53CTSCGAA | |
| SCHEMBL2126696 | 0.80 | MAPT (0.54) | KDM5AMAPTTP53CTSCPOLB | |
| SCHEMBL2873308 | 0.80 | KDM5A (0.51) | KDM5AMAPTTP53POLBGAA | |
| SCHEMBL2123865 | 0.79 | KDM5A (0.50) | KDM5AMAPTTP53GAAEGFR | |
| SCHEMBL2127738 | 0.77 | KDM5A (0.45) | KDM5AMAPTTP53POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | KDM5A 1592/4885MAPT 4045/4885TP53 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.